font size
Sign inprintPrint


Comparative Effectiveness Studies of Cancer Drugs Is Costly

NCI researchers say high cost of some drugs makes it difficult to assess them against cheaper treatments.

As the American Society of Clinical Oncologists, or ASCO, prepares to rate cancer drugs not only on effectiveness and safety but also on cost of treatment, two researchers from the National Cancer Institute published a perspective piece in the New England Journal of Medicine noting that the price of some cancer drugs are so high that they prevent “comparative effectiveness trials that would seek to establish equally effective but cheaper alternatives.” Read More
Other recent stories

Sign Up to recevie the Burrill Weekly Brief

Follow burrillreport on Twitter